Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegozafermin SC Injection Site PK Study in Healthy Participants
NCT07835243Phase 1Not yet recruiting
- Sponsor
- Roche
- Start
- Nov 2026
- Primary completion
- Mar 2027
01
Overview
Phase 1, randomised, open-label trial of pegozafermin in Nonalcoholic steatohepatitis (NASH) and hypertriglyceridemia (3 arms), sponsored by Roche. Primary endpoints: Maximum Observed Serum Concentration, Area Under the Serum Concentration-Time Curve From Time 0 to Last Measurable Concentration and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pegozafermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)hypertriglyceridemia
Beyond the preview
Go deeper on NCT07835243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835243.